Meta-Analysis of Safety Effectiveness Profile and Overall Response Rate of Metastatic Renal Cell Carcinoma Treatments

Abstract

Specific Aims: The aim of this project was to determine the overall efficacy of metastatic renal cell carcinoma pharmacotherapeutic agents as well as determine which chemotherapeutic treatment had the lowest side effect profile. Methods: Overall, a MESH database search was done in PubMed that pulled relative clinical trials that examined chemotherapeutic medications for metastatic renal cell carcinoma. From there the papers were analyzed based on particular demographics such as: Drug Treatment, Drug Comparator, Overall Survival, Progression Free Survival, and Overall Response Rate. This was done through a fixed effects analysis comparing the odds ratios for the different mediations. A network diagram was also developed to show the relationship of the studies. Data was then further analyzed for overall side effect profiles which looked at the total number of adverse events in a study. Main Results: The main result is that Nivolumab + Ipilimumab has the lowest Odds Ratio OR = 0.08 ( 0.03 – 0.21, 95% CI) when compared to Lenvatinib. This is in terms of overall response. With regards to the side effect profiles of the medications, Nivolumab vs Everolimus produced the lowest side effect profile with roughly 27%. Conclusions Nivolumab appears to be the medication that has the greatest overall response rate and least adverse side effect profile. This also depends if the medication is combined with Ipilimumab for greater overall treatment response.